Stock events for Hologic, Inc. (HOLX)
Over the past six months, Hologic's stock price has experienced a declining trend, falling by 24.7% as of March 19, 2025, and touching a 52-week low of $60.34 around March 13, 2025, attributed to macroeconomic headwinds and evolving geopolitical landscapes. In Q1 Fiscal 2025, Hologic reported adjusted EPS of $1.03 and revenue of $1.0218 billion. In Q2 Fiscal 2025, revenue was $1,005.3 million, and non-GAAP diluted EPS was $1.03. Hologic acquired Endomagnetics Ltd in Q4 Fiscal 2024 and completed the acquisition of Gynesonics in Q1 Fiscal 2025. The company repurchased 0.7 million shares for $58 million in Q4 Fiscal 2024, and 6.8 million shares for $517 million in Q1 Fiscal 2025.
Demand Seasonality affecting Hologic, Inc.’s stock price
There is no explicit mention or detailed analysis of demand seasonality for Hologic, Inc.'s products and services in the provided information.
Overview of Hologic, Inc.’s business
Hologic, Inc. is a medical technology company focused on improving women's health and well-being through early detection and treatment. It operates within the Healthcare sector, specifically in the Medical Equipment and Medical Instruments & Supplies industry. The company develops, manufactures, and supplies a diverse range of medical diagnostics, imaging systems, and surgical products, segmented into Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
HOLX’s Geographic footprint
Hologic is headquartered in Marlborough, Massachusetts, USA, and has a significant global presence with locations in over 36 countries. It distributes its products through direct sales, service personnel, and a network of independent distributors and sales representatives across North America, Europe, Asia Pacific, the Middle East, and Africa. Specific operational sites and subsidiaries are located in various U.S. states, Japan, the UK, Belgium, Chile, France, Germany, Denmark, Sweden, Australia, and Switzerland.
HOLX Corporate Image Assessment
Hologic has maintained a positive brand reputation, recognized as a "Great Place To Work" in 2024 and ranking #45 on Fortune's Best Workplaces for Parents™ and #13 on Fortune's Best Workplaces in Health Care™. Hologic's 3D Mammography System won the "Coolest Thing Made in Delaware Contest" in March 2024. No specific events negatively impacted Hologic's brand reputation in the past year.
Ownership
Hologic's ownership is predominantly institutional, with institutional shareholders holding approximately 98.07% of the company's shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., T. Rowe Price Investment Management, Inc., Morgan Stanley, State Street Corp, Victory Capital Management Inc, and Geode Capital Management, LLC. Carl C. Icahn is the largest individual shareholder, owning 12.63% of the company's shares. Hologic insiders collectively own 15.33% of the company.
Ask Our Expert AI Analyst
Price Chart
$65.16